Bioventix Plc · LSE:BVXP
Bioventix — FY2026 Earnings Presentation
26 slides from Bioventix's earnings presentation, October 2026
Slide 1: Final Results
Final Results October 2026 1
Slide 2: Contents
Contents 3 What we do 7 Market Opportunity 14 Financials 18 Our Strategy 20 Outlook 22 Appendices 2
Slide 3: What we do
What we do 3
Slide 4: Antibodies and Blood Testing
WHAT WE DO Antibodies and Blood Testing BLOOD SAMPLE VACUTAINER • Bioventix creates and manufactures sheep monoclonal antibodies (SMAs) • Customers incorporate these antibodies into reagent packs for use on blood-testing analysers AUTOMATED BLOOD TESTING • Superior antibodies can facilitate improved
Slide 5: Diagnostic Applications for SMAs
WHAT WE DO Diagnostic Applications for SMAs Thyroid Heart attack Neurology & Vitamin D Fertility Drug testing function & failure Alzheimer’s (testosterone, (25 - OH vitamin D) (thyroxine, T3) estradiol, (troponin, BNPs) (Taus) (THC) progesterone) Bioventix has a portfolio of ~30 antibodies that are
Slide 6: Antibodies and Business Dynamics
WHAT WE DO Antibodies and Business Dynamics 3–5 years to market ~1 year Antibody development 2–4 yrs Test development & approval • Creating a new panel of antibodies takes Bioventix around a year • Customers then typically spend two to four years, even for established diagnostics, prototyping the te
Slide 7: Market Opportunity
Market Opportunity 7
Slide 8: Alzheimer's (AD) in 2026
MARKET OPPORTUNITY Alzheimer’s (AD) in 2026 Alzheimer’s therapeutics Greater understanding of Licensed therapeutics 3 AD biology and Phase III trials 75 disease progression Phase II trials 165 Phase I trials 107 Greater AD diagnostics: RuO IVD understanding of underlying cell Roche 12 4 biochemistry
Slide 9: Alzheimer's Blood Tests
MARKET OPPORTUNITY Alzheimer’s Blood Tests Established blood Brain pathology A biomarker (candidate) N Total or brain - derived Amyloid plaques ( A) p - Tau217 Tau tangle formation ( T) eMTBR - Tau T Neurodegeneration ( N) Total brain - derived Tau ▪ Total p-Tau217 assays have now been approved for
Slide 10: eMTBR-Tau & Late-Stage Disease Assays
MARKET OPPORTUNITY eMTBR-Tau & Late-Stage Disease Assays Tau PET ▪ Phospho Tau217 tracks early-stage disease ▪ eMTBR-Tau – present at an even lower concentration - better tracks late-stage disease Sources - IVD: Alamar, Spear, Sysmex; Academic: Ashton, Karikari ▪ Potential utility for confirmation o
Slide 11: Alzheimer's SMAs: Commercialisation
MARKET OPPORTUNITY Alzheimer’s SMAs: Commercialisation Established blood R&D assay IVD clinical Partners/ Partners/ Brain pathology biomarker candidate launched assay IVD New HS Total or brain - derived Amyloid plaques (A) 3 3 p - Tau217 NEW Tau Tangle formation (T) eMTBR - Tau 2 Neurodegeneration (
Slide 12: Neurology: Research Pipeline
MARKET OPPORTUNITY Neurology: Research Pipeline Non-brain: ▪ Peripheral neuropathies Non-Alzheimers: ▪ Vascular dementia ▪ Rare dementias Alzheimers: ▪ Additional staging assays 12
Slide 13: Other Developments
MARKET OPPORTUNITY Other Developments AMYLOID (Pre-Diagnostics/Alzheimer’s): ARIA (amyloid-related imaging abnormality) is an important side-effect of new anti-amyloid drugs for Alzheimer’s. Pre-Diagnostics assays relate to amyloid metabolism and could help screen for ARIA vulnerable patients, befor
Slide 14: Financials
i. Bioventix Financials
Slide 15: Key Year-End Financials
FINANCIALS Key Year-End Financials FY 25 FY 26 FY26 Cavendish Forecast £ (‘000) (June year - end) (June year - end) (June year - end) Sales 13,120 12,970 12,500 (- 1%) P/(L) before tax 10,100 10,230 9,600 (adjusted) (adjusted: certain costs stripped out) (+1%) P/(L) after tax 7,580 7,610 7,200 (adju
Slide 16: FY26 Sales Mix
FINANCIALS FY26 Sales Mix self - funded contract R&D collaborative R&D -4% ← % change from 2024/25 • £555k neuro total was split: ‐ £257k royalties, up x3 from £75k ‐ £298 k physical SMA sales (down from £530k) • Siemens troponin revenues will -3% terminate in June 2032 -7% • 7 Steroids include estr
Slide 17: Sales Commentary
FINANCIALS Sales Commentary VITAMIN D TAU & NEURO Sales were slightly down but proved resilient in a difficult environment ▪ Royalties grew by x3 to £257k as more assays featuring SMAs reached the downstream market CORE HISTORIC ANTIBODIES ▪ Sales of purified antibodies for customers Tau assays are
Slide 18: Our Strategy
Our Strategy 18
Slide 19: Our Growth Strategy
OUR STRATEGY Our Growth Strategy Investment Neurology Historic Historic in our product products product Team portfolio portfolio Neurology products Neurology products • Strive to maintain revenues • Progress the commercialisation through the continued supply of existing Tau SMAs of high quality anti
Slide 20: Outlook
4 Bioventix Outlook
Slide 21: Outlook and Conclusion
Outlook and Conclusion and Sales of neuro SMAs have performed strongly and our extensive footprint at 1 customers bodes well for the future Our participation in the emergence of a new AD blood biomarker for Tau 2 tangle formation (eMTBR-Tau) is a major achievement Sales of our vitamin D antibody and
Slide 22: Appendices
Bio Appendices
Slide 23: Board of Directors
APPENDICES Board of Directors Peter Harrison Jo Pisani Ian Nicholson Bruce Hiscock Chris Yates Chief Executive Non-Executive Chairman Chief Financial Officer Non-Executive Director Officer Director >30 years experience of Chartered Accountant Appointed as a Bioventix Chartered Engineer with a >30 ye
Slide 24: Our Farnham Lab
APPENDICES Our Farnham Lab Purification and assay Technology Development Cell culture Bioreactor production Production capacity and final product storage have increased to support the • Staff continuity remains healthy neuro projects • One new science graduate from the locality started in October 20
Slide 25: Significant Shareholders
APPENDICES Significant Shareholders 5,224,860 Total shares Institution Shares % (1000s) (Oct 2026) Gresham House 628 12.0 Liontrust 572 11.0 From permissions, other Rathbone Investment 324 6.2 available data and TR-1 Peter Harrison 306 5.9 forms received as at Oct Premier Miton 263 5.0 2026 Raymond
Slide 26: Contact details
T: +44 (0)1252 728001 E: info@bioventix.com Postal address: Bioventix 7 Romans Business Park East Street Farnham GU9 7SX 26